Novozymes A/S

BATS-CHIXE:NSISBC Stock Report

Market Cap: DKK 182.8b

Novozymes Valuation

Is NSISBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of NSISBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: NSISBC (DKK388.6) is trading below our estimate of future cash flow value (DKK529.83)

Significantly Below Future Cash Flow Value: NSISBC is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NSISBC?

Key metric: As NSISBC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NSISBC. This is calculated by dividing NSISBC's market cap by their current earnings.
What is NSISBC's PE Ratio?
PE Ratio41x
Earnings€596.70m
Market Cap€24.45b

Price to Earnings Ratio vs Peers

How does NSISBC's PE Ratio compare to its peers?

The above table shows the PE ratio for NSISBC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.3x
CRDA Croda International
68.4x24.93%UK£4.2b
ELM Elementis
18.8x11.99%UK£874.9m
FRES Fresnillo
20.5x15.20%UK£21.2b
TET Treatt
41.4x25.01%UK£178.6m
NSISBC Novozymes
41x14.03%DKK 182.8b

Price-To-Earnings vs Peers: NSISBC is expensive based on its Price-To-Earnings Ratio (41x) compared to the peer average (37.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does NSISBC's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies10PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NSISBC is expensive based on its Price-To-Earnings Ratio (41x) compared to the European Chemicals industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is NSISBC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NSISBC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41x
Fair PE Ratio22.1x

Price-To-Earnings vs Fair Ratio: NSISBC is expensive based on its Price-To-Earnings Ratio (41x) compared to the estimated Fair Price-To-Earnings Ratio (22.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NSISBC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 388.60
DKK 460.94
+18.61%
9.51%DKK 552.00DKK 362.00n/a17
Jun ’27DKK 376.10
DKK 460.94
+22.56%
9.51%DKK 552.00DKK 362.00n/a17
May ’27DKK 395.70
DKK 452.18
+14.27%
10.79%DKK 560.00DKK 362.00n/a17
Apr ’27DKK 388.65
DKK 459.53
+18.24%
11.62%DKK 560.00DKK 362.00n/a17
Mar ’27DKK 371.20
DKK 457.50
+23.25%
12.17%DKK 560.00DKK 362.00n/a18
Feb ’27DKK 384.20
DKK 467.96
+21.80%
12.58%DKK 560.00DKK 375.00n/a18
Jan ’27DKK 407.60
DKK 471.07
+15.57%
12.36%DKK 560.00DKK 380.00n/a17
Dec ’26DKK 404.80
DKK 471.34
+16.44%
12.35%DKK 560.00DKK 380.00n/a17
Nov ’26DKK 387.25
DKK 465.13
+20.11%
12.03%DKK 569.00DKK 376.00n/a17
Oct ’26DKK 390.35
DKK 466.55
+19.52%
12.04%DKK 569.00DKK 380.00n/a17
Sep ’26DKK 407.35
DKK 469.48
+15.25%
11.87%DKK 569.00DKK 380.00n/a17
Aug ’26DKK 425.40
DKK 500.12
+17.56%
12.86%DKK 577.00DKK 390.00n/a17
Jul ’26DKK 450.90
DKK 503.88
+11.75%
12.31%DKK 577.00DKK 389.00n/a17
Jun ’26DKK 462.70
DKK 496.22
+7.25%
11.52%DKK 577.00DKK 389.00DKK 376.1017
May ’26DKK 411.70
DKK 484.94
+17.79%
11.73%DKK 576.00DKK 388.00DKK 395.7016
Apr ’26DKK 399.35
DKK 491.31
+23.03%
11.81%DKK 598.00DKK 388.00DKK 388.6516
Mar ’26DKK 427.60
DKK 489.12
+14.39%
11.26%DKK 598.00DKK 388.00DKK 371.2016
Feb ’26n/a
DKK 486.24
0%
11.77%DKK 598.00DKK 372.00DKK 384.2016
Jan ’26n/a
DKK 485.12
0%
11.97%DKK 598.00DKK 364.00DKK 407.6016
Dec ’25DKK 416.10
DKK 484.05
+16.33%
11.69%DKK 586.00DKK 364.00DKK 404.8016
Nov ’25DKK 431.25
DKK 488.00
+13.16%
11.08%DKK 560.00DKK 360.00DKK 387.2515
Oct ’25DKK 475.30
DKK 487.50
+2.57%
10.97%DKK 560.00DKK 360.00DKK 390.3516
Sep ’25DKK 467.65
DKK 464.99
-0.57%
11.12%DKK 540.00DKK 360.00DKK 407.3516
Aug ’25DKK 429.75
DKK 458.43
+6.67%
10.63%DKK 540.00DKK 360.00DKK 425.4016
Jul ’25DKK 423.60
DKK 449.81
+6.19%
10.68%DKK 540.00DKK 350.00DKK 450.9016
Jun ’25n/a
DKK 437.35
0%
9.11%DKK 500.00DKK 350.00DKK 462.7014
DKK 456.59
Fair Value
14.9% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 20:31
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander SloaneBarclays
Cezara LozneanuBarclays
Sebastian SatzBarclays